Leede Financial Has Negative Outlook of THTX FY2025 Earnings

Theratechnologies Inc. (NASDAQ:THTX - Free Report) - Stock analysts at Leede Financial dropped their FY2025 EPS estimates for shares of Theratechnologies in a research note issued on Monday, April 14th. Leede Financial analyst D. Loe now forecasts that the company will post earnings per share of ($0.17) for the year, down from their prior estimate of $0.06. The consensus estimate for Theratechnologies' current full-year earnings is $0.01 per share.

Several other equities research analysts have also recently issued reports on the stock. Jones Trading raised shares of Theratechnologies from a "hold" rating to a "strong-buy" rating in a research note on Friday, April 11th. Research Capitl upgraded Theratechnologies to a "strong-buy" rating in a report on Friday, February 14th.

Theratechnologies Stock Down 1.9 %

Shares of NASDAQ THTX traded down $0.05 during midday trading on Wednesday, hitting $2.52. The stock had a trading volume of 758,784 shares, compared to its average volume of 770,955. Theratechnologies has a 1 year low of $1.08 and a 1 year high of $3.13. The company has a market capitalization of $115.87 million, a PE ratio of -25.20 and a beta of 1.11. The stock has a 50 day simple moving average of $1.71 and a 200-day simple moving average of $1.56.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in THTX. National Bank of Canada FI grew its holdings in shares of Theratechnologies by 29.4% during the 3rd quarter. National Bank of Canada FI now owns 186,815 shares of the company's stock worth $232,000 after purchasing an additional 42,435 shares during the period. Harbour Investments Inc. lifted its holdings in shares of Theratechnologies by 20.0% in the 4th quarter. Harbour Investments Inc. now owns 87,772 shares of the company's stock worth $159,000 after acquiring an additional 14,655 shares during the last quarter. Wealthspire Advisors LLC boosted its position in shares of Theratechnologies by 39.0% during the 4th quarter. Wealthspire Advisors LLC now owns 71,250 shares of the company's stock worth $129,000 after purchasing an additional 20,000 shares during the period. Hillsdale Investment Management Inc. purchased a new stake in Theratechnologies in the fourth quarter valued at approximately $108,000. Finally, Cyndeo Wealth Partners LLC acquired a new stake in shares of Theratechnologies in the first quarter valued at $42,000.

About Theratechnologies

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.